A randomized trial of patellofemoral bracing for treatment of patellofemoral osteoarthritis  by Hunter, D.J. et al.
Osteoarthritis and Cartilage 19 (2011) 792e800A randomized trial of patellofemoral bracing for treatment of patellofemoral
osteoarthritis
D.J. Hunter yz*, W. Harvey y, K.D. Gross xk, D. Felson k, P. McCree y, L. Li y, K. Hirko y, B. Zhang k, K. Bennell{
yNew England Baptist Hospital, 125 Parker Hill Ave, Boston, MA 02120, USA
zNorthern Clinical School, University of Sydney, Sydney, Australia
xMGH Institute of Health Professions, Boston, MA, USA
kBoston University School of Medicine, 750 Albany St, Boston, MA 02118, USA
{University of Melbourne, Melbourne, VIC, Australiaa r t i c l e i n f o
Article history:
Received 12 July 2010
Accepted 17 December 2010
Keywords:
Patellofemoral osteoarthritis
Brace* Address correspondence and reprint requests to
Department, Royal North Shore Hospital, St Leonards
E-mail address: David.Hunter@sydney.edu.au (D.J.
1063-4584/$ e see front matter  2010 Osteoarthriti
doi:10.1016/j.joca.2010.12.010s u m m a r y
Purpose: The number of effective knee osteoarthritis (OA) interventions, especially those tailored to
speciﬁc compartmental involvement, are small. The objective of this study was to determine the efﬁcacy
of a realigning patellofemoral (PF) brace in improving pain and function among persons with symp-
tomatic lateral PF OA.
Method:We conducted a double blind, randomized crossover trial of a realigning PF brace for persons with
lateral PF OA. Participants had lateral PF OA with anterior knee symptoms on most days of the month,
lateral PF joint space narrowing, and radiographic evidence of a deﬁnite osteophyte in the PF joint. We
compared two treatments: (1) Control treatment consisting of a BioSkin Q Brace with patellar realigning
strap removed; and (2) Active treatment consisting of a realigning BioSkin Q Brace with the strap applied.
For each participant, the trial lasted 18 weeks, including 6 weeks each of active and control treatment
period separated by a 6-week washout period. The order of treatments was randomized. The primary
outcome was change in knee pain on the visual analog scale (VAS). Secondary outcomes included
WOMAC pain, function, and stiffness. An unstructured correlation matrix for observations within
participants was used in generalized estimating equation ﬁtting to derive a linear regression model that
expressed the relation between the intervention and change in VAS pain.
Results: 80 participants (63 F) with a mean age and body mass index of 61 years and 28 kg/m2,
respectively, were randomized by order of treatment. A model examining the main effects for change in
VAS knee pain (0e100) demonstrated no signiﬁcant treatment effect (0.68 VAS units, 95% CI: 6.2, 4.8
units, P¼ 0.81) and no differential carryover effect. There was also no signiﬁcant difference between
active and control treatments for WOMAC pain, function, or stiffness outcomes.
Conclusion: The effects of a speciﬁc realigning PF brace are not of clinical or statistical signiﬁcance.
NIH Clinical Trials Registry NCT00381563
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
The patellofemoral (PF) joint is involved in approximately 65% of
persons with knee OA; predominantly within the lateral PF
compartment1,2. Relatively little attention has been paid to the PF
joint in knee OA, despite suggestions that disease in this
compartment may be strongly correlated with lower extremity
disability3, and that involvement of the PF joint is more highly
correlated with knee pain in OA than is isolated involvement of the: D.J. Hunter, Rheumatology
2065, Australia.
Hunter).
s Research Society International. Ptibiofemoral (TF) joint4e6. Unfortunately, the majority of epidemi-
ologic studies examining risk factors for OA have focused on the TF
joint with little heed paid to the unique biomechanics of the PF
joint7e9. This line of research is needed as the designs of the PF and
TF compartments reﬂect unique functions and mechanics10. These
differences in design and function are likely to have important
implications for treatment. Given the heterogeneity of OA as
a disease process and its protean symptomatic presentations,
therapeutic interventions for knee OA should be guided by an
awareness of which joint compartments are involved. At present,
there are few effective conservative interventions for relieving pain
and improving function in knee OA and even fewer that are
speciﬁcally targeted to the unique mechanics of the PF
compartment.ublished by Elsevier Ltd. All rights reserved.
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of the patella that may lead to an aberrant dispersion of forces
transmitted through the PF joint11. Patellar malalignment may
cause an aberrant dispersion of patellofemoral joint reaction (PFJR)
forces and, by this mechanism, predispose to pain and/or structural
damage11e13. Of primary concern is excessive lateral translation in
the coronal plane and excessive lateral tilt in the axial plane14.
Uncontrolled data suggests that patellae that are well-aligned
centrally in the trochlear groove, without lateral coronal or axial
malalignment, may be less likely to develop osteoarthritis
(OA)15e17. Conversely, persons with lateral PF OA often present with
laterally malaligned patellae and maltracking that is associated
with symptoms18. Prior studies have demonstrated that patellar
taping can lead to marked short-term improvements in knee
pain19,20 although it is not altogether clear that the mechanism
involves substantive changes in patellar alignment21e28. One
possible explanation of the favorable inﬂuence that patellar taping
has on symptoms is that it leads to sufﬁcient improvements in PF
alignment (by reducing lateral displacement and tilt) to improve
joint contact area and consequently impact joint stress. Some
evidence suggests that realigning PF braces can lead to similar
short-term improvements in joint contact area23,24.
Given the increased likelihood of patellarmalalignment in people
with PF OA and the link between malalignment and symptoms,
interventions that aim to improve patellar alignment may be efﬁ-
cacious. If onewere able to improve PF alignmentwith application of
a PF brace with a realigning strap in persons with PF OA, similar
improvements in symptoms to those seen in response to patellar
taping may be possible3,29. Despite its proven efﬁcacy, patellar
taping30 has not been widely adopted clinically for the treatment of
patients with knee OA19,20. This probably results from the fact that it
is complicated to administer and often difﬁcult for older patients to
apply independently. Skin irritation occurs in a signiﬁcant minority
of individuals, and removal of the adhesive tape is often uncom-
fortable for patients with body hair. Furthermore, there are no
studies assessing the longer-term efﬁcacy of patellar taping. In
contrast, realigning PF braces may accomplish many of the
mechanical effects of patellar tape, while avoiding these limitations.
More speciﬁcally, PF braces are easy to apply during long-term
repeated use, and are far less likely to cause skin irritation.
Given the pressing need for effective interventions for PF OA, the
speciﬁc aim of this trial was to undertake a double-blind,
randomized crossover clinical trial among patients with PF OA to
determine whether use of a realigning PF brace for 6 weeks leads to
greater pain reduction than does an equivalent period of use of the
same brace without a patellar realigning strap.
Methods
Participants
FromMarch 2006 to December 2009, we recruited persons with
lateral PFOA fromprevious trial databases inwhich participants had
been originally recruited from community volunteers. Participants
were required to have knee pain on most days and either isolated
lateral PF OA or mixed lateral PF and TF OA. Participants had skyline
and bilateral standing AP radiographs during the screening phase.
We used a radiographic deﬁnition of PF OA from the skyline view
and adopted scoring criteria that have been previously described31.
Brieﬂy, individual radiographic features and overall grades of OA in
the PF compartment were read according to the following schemes
using the Osteoarthritis Research Society International atlas; joint
space narrowing (JSN) and osteophytes, both on 0e3 scales. A knee
was deﬁned as having PF OA if there was an osteophyte of severity
grade 2 OR if there was moderate to severe JSN (grade 2) withconcurrent grade 1 osteophyte in the PF joint31. We recruited
persons with predominantly lateral PF OA; deﬁned as lateral >
medial PF JSN on skyline view.
PF OA was deﬁned as compartment-speciﬁc (or isolated) if there
was not concomitant TF OA. Radiographic TF OA was deﬁned as
a Kellgren and Lawrence (K/L) grade of 2 on the Anteroposterior
(AP) view32. Participants with concomitant TF OA (in addition to
radiographic lateral PF OA) were admitted if their source of symp-
toms for self-reported pain location or physical examination was
consistent with PF disease. The judgment was based on consider-
ation of: (1) Which activities brought on the knee pain; pain on stair
climbing and/or rising from a chair was considered typical of PF OA,
whereas pain walking on level ground was considered more typical
of the TF joint; (2) Where the pain was located in the knee; pain in
the posterior aspect of the knee or in the region of the pes anserine
bursawas considered unlikely to be from the PF joint; and (3)Where
tenderness was located on examination; tenderness with patellar
mobilization was considered typical of PF OA.
For participants in whom both knees met the eligibility criteria,
we treated the more symptomatic of the two knees to optimize
symptom attribution for self-reported assessments.
Exclusion criteria included:
1. Bed or wheelchair bound persons or persons who usually used
an ambulation aid to walk, such as a cane, crutch, or walker.
2. Lower extremity pain emanating from the back or hip more
than from the knee as determined by screening questionnaire
and physical examination.
3. Low initial pain score on VAS (<4 out of 10) on phone screening
and visit 1 screening (Note: bracing commenced after
screening and randomization).
4. Planning to move from area within 10 months of study
screening or had any extended vacation plans of more than 1
month during the study period.
5. Symptomatic comorbid disease that limited activities more
than knee pain (such as heart or lung problems) per screening
questionnaire.
6. Receiving corticosteriod injection in themonth prior to starting
the trial, or hyaluronan injection in the 6-month period prior to
the trial.
7. Bilateral total knee replacements or plan for total knee
replacement in next 6 months for the signal knee.
8. Likely difﬁculty with brace ﬁtting or brace slippage due to knee
or thigh dimensions inappropriate for brace ﬁtting (knee
circumference >55 cm). Prior prescription brace use or aller-
gies to neoprene.
9. Other known causes of arthritis, including rheumatoid
arthritis, systemic lupus erythema, gout, psoriatic arthritis, or
pseudogout as determined by self reported diagnosis.
10. Skin breakdown at the site where the brace was to be applied.
11. Failure to pass run-in test or unable to properly ﬁt the brace
during the run-in period.
12. Inability to complete the self-reported forms in English.
Procedures
We performed a randomized, crossover, double-blind (partic-
ipant and assessor) controlled trial. It was prospectively registered
with the NIH Clinical Trials Registry NCT00381563. The Boston
University IRB and New England Baptist Hospital Human Research
Ethics Committee approved the study and all participants
provided written informed consent. IRB approval was obtained on
July 13th 2006, the ﬁrst participant was enrolled in December
2006 and the last participant completed the study on November
3rd 2009.
D.J. Hunter et al. / Osteoarthritis and Cartilage 19 (2011) 792e800794The trial included a run-in period inwhich therewas a screening
phone call, a visit 2 weeks later (pre-randomization screening visit),
and a randomization visit 2 weeks after the initial visit. During the
2-week run-in period, participants wore a circumferential, elastic
brace strap with an attached New Lifestyles NL-1000 accelerometer
(New Lifestyles, Inc, Lees Summit, MO) to monitor usage. Partici-
pants were instructed to wear the brace strap for a minimum of 4 h
per day, and to record their perceived usage in a participant log33.
After the run-in showed acceptable usage (deﬁned as wearing
brace for at least 4 h per day) and following baseline outcome
assessment, patients were randomized to receive either Treatment
A or Treatment B ﬁrst for 6 weeks, followed by a 6-week washout
period before crossing over to the other treatment group (B or A)
for the second 6-week period of treatment.
Randomizationwas performed outside of the clinic by a biostatis-
tician and concealed from all other study investigators. Randomiza-
tion was stratiﬁed by the presence or absence of X-ray TF OA and by
gender, as there may be differences in symptom and disease location
by gender3. We preserved allocation concealment by having the
randomization codes held by thebiostatistician external to the clinical
trial operations.Group allocationwas revealed froma sealed envelope
to the research coordinator at the time of the randomization visit.
Intervention
The goal of this study was to evaluate the therapeutic effects of
a realigning PF brace in comparison with a non-realigning placebo
brace. The two treatments were: Treatment A (Control) a BioSkin Q
Brace (Cropper Medical Inc., Ashland, OR) with the realigning T
strap removed and Treatment B (Active) the BioSkin Q Brace with
the realigning T strap intact (see Fig. 1). Participants were asked to
wear the assigned knee brace for a minimum of 4 h per day during
the treatment period.
The Q Brace has an anterior aperture to admit the patella. The
“T” strap has two arms that adhere medially with Velcro and has
one attachment laterally. The application is intended to control the
direction of traction on the patella. In particular, the strap aimed to
apply a medial glide to minimize lateral movement of the patella.
The brace is made of a material trademarked as Bio Skin. Bio Skin
is an elastic, latex free, hypo-allergenic material that provides
compression and moisture vapor transfer. The Q Brace can beFig. 1. BioSkin Q Brace with the realigning T strap intact (Figure Left). Positioning and
conﬁguration of the T strap overlying the brace delineated in red with patella aperture
facing anteriorly and strap cupping the lateral aspect of the patella for application of
a force to produce a medial patellar glide (Figure Right).purchased off-the-shelf in a range of sizes for different knee and
thigh circumferences. In this study, ﬁtting and positioning of the
knee brace was performed by a trained investigator (KH) who also
positioned and applied the “T” strap. Marks were placed on the
brace to indicate where the “T” strap should be reapplied for daily
use. The person teaching the participant how to correctly apply the
brace was, by necessity, not blinded.
In all other respects, we attempted to conduct a blinded trial.
Our description of the treatments to the participants was that we
were comparing two types of braces for their PF OA without
specifying which one constituted active treatment. The active and
control braces were also identical apart from the application of the
realigning T strap.
Trial outcomes
All participants were evaluated by the same blinded assessor.
The primary outcome was change in knee pain on the visual analog
scale (VAS). Participants rated the average severity of knee pain
over the previous week. Change in pain was measured on
a 0e100 mm horizontal VAS with terminal descriptors of (0¼ no
pain; 100¼maximal pain)34. This was assessed at baseline and at
each follow-up visit week 1, 3 and 6 of each treatment phase.
Secondary outcomes included:
1. Western Ontario and McMaster Universities Arthritis Index
(WOMAC) Pain Subscales (Likert form)35 (primary treated
knee). Pain was assessed using the pain subscale of the Likert
version of the WOMAC. This disease-speciﬁc measure is reli-
able, valid and responsive and consists of 5 pain items, 17
function items and 2 stiffness items each using a ﬁve-point
scale to score each item, where higher scores indicate worse
symptoms35.
2. WOMAC Function Subscale. Difﬁculty with physical function
was assessed using the physical function subscale of the Likert
version of the WOMAC.
3. WOMAC Stiffness Subscale Stiffness was assessed using the
stiffness subscale of the Likert version of the WOMAC.
Adherence
We used a number of different methods tomonitor and improve
adherence. First, we screened participants during the run-in after
using the brace strap and accelerometer to assess whether they
were willing to wear the brace therapy for their PF OA. Second, we
inquired in a detailed fashion about adherence with use of bracing
and evaluated the participant’s log of brace usage at each visit. We
called the participants every week during the active phases of the
trial (0e6 weeks; 12e18 weeks).
Statistical analysis
Analysis of the trial focused on the primary outcome measure,
change in pain during treatment. The purpose was to estimate
the effect of a realigning strap on pain reduction in comparison
with a control brace. Because there were repeated assessments
of the VAS and WOMAC pain scores within each treatment
period, we averaged the mid-treatment (week 3 of each treat-
ment phase) and end of treatment (week 6 of each treatment
phase) pain scores to reduce the variability of assessment36.
Based on taping studies that showed immediate effects on
symptoms, we expected the effects of the PF brace to fully
manifest after 3 weeks of treatment, so averaging of mid-treat-
ment and end of treatment pain scores should not have biased
estimates of treatment effect.
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using a linear mixed-effect model with unstructured covariance
structure for repeated measurements within participants. In these
regression models, the baseline score of each phase was used as
a predictor in addition to indicators of treatment and period and an
interaction of treatment by period. In a two-period crossover trial,
the treatment by period interaction is equivalent to the carryover
effect, so this provided another method of assessing the carryover
effect. The treatment effect in this analysis would have been
diminished if there was a carryover effect of the ﬁrst treatment.
However, the washout period of 6 weeks between treatments was
intended to remove any such carryover effect. We also used
a formal statistical test to assess for carryover effect37. This analysis
approximated an intent-to-treat approachwith the last observation
brought forward for missing values.
The secondary analysis of pain, function and stiffness using the
WOMAC subscales proceeded in the samemanner as is outlined for
the pain scale above. We also performed the crossover analysis
stratiﬁed by form of OA: participants with isolated PF OA in one
stratum and those with TF involvement in the other stratum38.
All statistical analyses were performed using version 9 of the
SAS statistical analysis software package.
Power estimates
Based upon the results from the Hinman19, Horlick39 and Kirk-
ley40 studies of knee taping and bracing, we anticipated a conser-
vative treatment effect difference of 30% in pain and function. We
estimated a correlation of 0.6 in the primary outcome measure
(VAS pain) for measures taken within a participant. In all of theseContacts
N= 592
Screened
N=145
Intervention 
to placebo 
N=41
Randomiz
Subjects
N=80
Completed 
trial
N=34
Withdrawn (n=7) 
Pain/swelling (n=2) 
Lost to follow-up (n=2) 
Brace fitting issues (n=2) 
Other health issues (n=1) 
Fig. 2. Flow chart ocalculations we used the comparison between the therapeutic tape
and control tape groups. Hinman et al.19 found a signiﬁcant differ-
ence between the treatments for VAS pain with a mean difference
of 1.3 on a 10 cm scale.
We also planned an a priori stratiﬁed analysis for PF OA and
mixed PF and TF OA to assess for differences in treatment effect
between these two groups. For VAS pain in a crossover analysis, just
under 45% of the participants would need to have isolated PF OA to
detect a treatment difference of 0.7 cm on the VAS (0e10 cm scale)
with 80% power (two sided alpha, P¼ 0.05). In the analysis of all
participants, a treatment difference of 0.46 in VAS pain was
detectable with 80% power. To achieve 80% power to detect
a difference of 0.7, 43% of participants would need to have isolated
PF OA. To achieve 80% power to detect a difference of 0.9, 26% of
participants must have isolated PF OA. Thus, in order to be
conservative we recruited 40 persons with isolated PF OA.
As we were interested in both the crossover design and phase 1
analysis, we assessed the power with 80 participants to assess
difference in each. The treatment differences on a 0e10 cm VAS
where the power reaches 80% were as follows: difference in VAS
pain detectable with cross-over analysis approach ¼0.46, and
difference in VAS pain detectable with period 1 analysis approach
¼1.30.
Results
Of the 592 potential participants who were contacted by phone,
145 were eligible for a screening visit. The major reasons for inel-
igibility on phone screening were insufﬁcient pain (n¼ 125), prior
brace use (n¼ 88), current cane or walker use (n¼ 60), and a prior 
 
ed 
 
Placebo to 
Intervention 
N=39
Completed 
trial  
N=33
Excluded (n=65) 
Ineligible on x-ray (n=57) 
Ineligible on clinical exam (n=7) 
Medication use (n=1)
Excluded (n=447) 
Insufficient pain (n=125) 
Past brace use (n=88) 
Cane, walker use (n=60) 
Previous diagnosis (n=58) 
Unable to complete in English 
(n=25) 
Excluded medication use 
(n=24) 
Declined (n=24) 
Moving/vacation (n=22) 
Unable to schedule (n=17) 
Other study participation (n=3) 
Allergies to neoprene (n=1) 
Withdrawn (n=6) 
Pain/swelling (n=2) 
Scheduling difficulties (n=2) 
Other health issues (n=1) 
Had Synvisc injection (n=1) 
f participants.
Table I
Baseline participant characteristics according to assigned initial treatment
Characteristics Active brace to
control brace
(n¼ 41)
Control brace to
active brace
(n¼ 39)
Age, mean standard deviation
(SD) years
60 (9.7) 61 (9.1)
Male sex, % 9 (22.5%) 8 (20.5%)
Body mass index, mean SD kg/m2 27.7 (12.5) 27.4 (14.0)
Kellgren/Lawrence grade 2, % 24 (58.5%) 21 (53.8%)
VASy pain score, mean SD
(0e100 scale)
45.2 (27.4)
range: 1e100,
Median: 38
35.4 (24.8)
range: 1e87,
Median: 26
WOMAC* pain score, mean SD
(0e20 scale)
7.8 (3.6) 7.2 (3.9)
K/L Grade signal knee:
Median {range}
2 (0e4) 2 (0e4)
n (%) Grade 0 7 (17%) 8 (21%)
n (%) Grade 1 10 (24%) 10 (26%)
n (%) Grade 2 6 (15%) 6 (15%)
n (%) Grade 3 13 (32%) 10 (26%)
n (%) Grade 4 5 (12%) 5 (13%)
Lateral PF JSN Grade signal knee:
Median {range}
2 (0e3) 2 (0e3)
n (%) Grade 0 3 (7%) 3 (8%)
n (%) Grade 1 17 (41%) 14 (36%)
n (%) Grade 2 11 (27%) 15 (38%)
n (%) Grade 3 10 (24%) 7 (18%)
* WOMAC eWestern Ontario and McMaster Universities Arthritis Index.
y VAS pain score at commencement of bracing.
Fig. 3. Interaction between treatment and period effect for VAS Pain.
Table IIa
Predictors of VAS pain scores during the crossover trial*
Predictor Model 1 Model 2
Baseline VAS pain score
(95% conﬁdence interval)
P-value
0.55
(0.41, 0.68)
<0.0001
0.56
(0.43, 0.69)
<0.0001
Treatment
(95% conﬁdence interval)
P-value
3.71
(7.23, 14.65)
0.5010
0.68
(6.20,4.84)
0.8055
Treatment, period 1 vs period 2
(95% conﬁdence interval)
P-value
0.89
(9.33,11.11)
0.8627
3.06
(8.82, 2.71)
0.2934
Period by treatment interactiony
(95% conﬁdence interval)
P-value
7.70
(8.89, 24.29)
0.3573
* Values for model predictors are beta coefﬁcients. For treatment as a predictor,
a value of xmeans that active treatment was associated with a x lower score on the
VAS pain scale compared with control treatment. An unstructured correlation
matrix for observations within participants was used in generalized estimating
equation ﬁtting of the marginal model (1). Model 2 was conducted with exclusion of
the differential carryover effect.
y Tests whether treatment effects differed according to use in period 1 or period 2,
constituting the differential carryover effect.
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who had a screening visit, 80 (40 with isolated PF OA and 40 with
mixed PF and TF OA) were found to be eligible and were random-
ized. Themost common reason for ineligibility at the screening visit
was failure to fulﬁll radiographic entry criteria (n¼ 57). Sixty seven
participants (84%) completed the 18-week trial. Figure 2 shows the
ﬂow of participants through the trial.
Forty-one participants were randomized to receive the active
brace ﬁrst and 39 to receive the control brace ﬁrst. There were no
statistically signiﬁcant differences in age, gender, body mass index
(BMI), radiographic severity or baseline VAS pain or WOMAC pain
score between these two treatment order groups (Table I). The
median K/L grade and lateral PF JSN grade for the study sample
signal kneewere both 2. Demographic and clinical characteristics of
the 13 participants who withdrew from the study did not differ
substantially from those who remained (data not shown).
When analyzing the crossover trial ﬁndings, we ﬁrst tested for
treatment period and differential carryover effects (Fig. 3 and Table
IIaed). The treatment effect of the realigning strap was not signiﬁ-
cant for VAS painwith a 3.71 unit difference (95% conﬁdence interval
(CI):7.23,14.65). The differential carryover was a 7.7 unit difference
in the VAS pain score (P¼ 0.36), showing that the comparison of
treatment efﬁcacy was not signiﬁcantly different if the patients were
randomized to the activeor control braceﬁrst. Therefore,we removed
the carryover term from the model. In Model 2, after excluding the
differential carryover effect and adjusting for baseline pain score, the
active intervention had no signiﬁcant effect on VAS painwith a 0.7
unit (0.07 cm) difference (95% CI: 6.2, 4.8 units; P¼ 0.81). The
study was powered to detect a 0.7 cm on the VAS (0e10 cm scale)
which is still less than that which is clinically signiﬁcant41,42.
Further examination of the effects of PF bracing onWOMAC pain
(Fig. 4 and Table IIb), WOMAC Function (Table IIc) and WOMAC
Stiffness (Table IId) revealed similar results with no signiﬁcant
carryover effect and no signiﬁcant treatment effect. In Model 2,
after excluding the differential carryover effect and adjusting for
baseline WOMAC pain score, the active intervention had no
signiﬁcant effect onWOMAC pain with a 0.11 unit difference (95%CI: 0.66, 0.88 units; P¼ 0.77). Similar effects were seen for
WOMAC function 0.02 unit difference (95% CI: 2.83, 2.79 units;
P¼ 0.99) and WOMAC stiffness 0.11 unit difference (95%
CI: 0.53, 0.32 units; P¼ 0.61).
Table III shows that the average participant was adherent (self-
reported from diary) with a mean of 4.8 h per day of use in the
active brace and 4.3 h per day for the control brace. Most partici-
pants wore the brace for more than 3 h per day. The adverse events
were generally minimal with no substantive differences between
interventions. However, four of the people who withdrew from the
study cited increased knee pain and/or foot/ankle swelling and two
people withdrew due to ﬁtting issues. None of the remaining
participants who experienced an adverse event in the trial required
either increased analgesia or withdrawal of the brace.
Additional analyses limited to phase 1, determining the effect of
isolated PF OA vs mixed PF and TF OA, in addition to effects of
gender showed results consistent with those already presented and
are not further presented here.Discussion
The development of efﬁcacious, conservative, non-pharmaco-
logic treatment approaches that are capable of ameliorating the
Table IIb
Predictors of WOMAC pain scores during the crossover trial*
Predictor Model 1 Model 2
Baseline WOMAC pain score
(95% conﬁdence interval)
P-value
0.56
(0.43, 0.69)
<0.0001
0.58
(0.45, 0.71)
<0.0001
Treatment
(95% conﬁdence interval)
P-value
1.33
(0.22, 2.88)
0.0912
0.11
(0.66, 0.88)
0.7744
Treatment, period 1 vs period 2
(95% conﬁdence interval)
P-value
1.24
(0.19,2.67)
0.0877
0.16
(0.62, 0.94)
0.6883
Period by treatment interactiony
(95% conﬁdence interval)
P-value
2.17
(0.24, 4.57)
0.0769
* Values for model predictors are beta coefﬁcients. For treatment as a predictor,
a value of xmeans that active treatment was associated with a x lower score on the
VAS pain scale compared with control treatment. An unstructured correlation
matrix for observations within participants was used in generalized estimating
equation ﬁtting of themarginal model (1). Model 2 was conducted with exclusion of
the differential carryover effect.
y Tests whether treatment effects differed according to use in period 1 or period 2,
constituting the differential carryover effect.
Table IId
Predictors of WOMAC stiffness scores during the crossover trial*
Predictor Model 1 Model 2
Baseline WOMAC stiffness score
(95% conﬁdence interval)
P-value
0.65
(0.52, 0.78)
<0.0001
0.67
(0.54, 0.80)
<0.0001
Treatment
(95% conﬁdence interval)
P-value
0.23
(0.49, 0.95)
0.5293
0.11
(0.53, 0.32)
0.6129
Treatment, period 1 vs period 2
(95% conﬁdence interval)
P-value
0.26
(0.39, 0.91)
0.4256
0.02
(0.46, 0.42)
0.9314
Period by treatment interactiony
(95% conﬁdence interval)
P-value
0.55
(0.41, 1.51)
0.2548
* Values for model predictors are beta coefﬁcients. For treatment as a predictor,
a value of xmeans that active treatment was associated with a x lower score on the
VAS pain scale compared with control treatment. An unstructured correlation
matrix for observations within participants was used in generalized estimating
equation ﬁtting of the marginal model (1). Model 2 was conducted with exclusion of
the differential carryover effect.
y Tests whether treatment effects differed according to use in period 1 or period 2,
constituting the differential carryover effect.
D.J. Hunter et al. / Osteoarthritis and Cartilage 19 (2011) 792e800 797symptoms and improving the structure of knee OA is an important
research objective43. Despite their current under-emphasis in
clinical trials and practice, therapies targeting the pathomechanics
of OA are likely to be efﬁcacious44. Unfortunately, we have not
found any therapeutic clinical effects from the application of
a brace with a realigning strap designed to improve PF alignment in
persons with lateral PF OA compared with an identical brace
without the realigning strap. Although participants were adherent
to the intervention in this trial and the application of the brace was
generally well-tolerated, there was little therapeutic beneﬁt to be
gained by the addition of a realigning strap to the brace.
The underlying aim of this study was to assess the patellar
realigning effect of the strap on symptoms. The rationale behind this
is that people with lateral PF OA have altered alignment (including
lateral displacement and tilt) and that this maltracking is associated
with symptoms18. Hence if we were to correct maltracking, we
should see a reduction in symptoms. This trial demonstrated that
the addition of a realigning strap did not lead to a reduction of
symptoms compared to the same bracewithout the strap. There are
a number of possible reasons why this may be the case and why we
have found no signiﬁcant treatment effect in this trial.Table IIc
Predictors of WOMAC function scores during the crossover trial*
Predictor Model 1 Model 2
Baseline WOMAC function score
(95% conﬁdence interval)
P-value
0.80
(0.69, 0.92)
<0.0001
0.81
(0.70, 0.92)
<0.0001
Treatment
(95% conﬁdence interval)
P-value
0.70
(4.62, 6.01)
0.7943
0.02
(2.83,2.79)
0.9878
Treatment, period 1 vs period 2
(95% conﬁdence interval)
P-value
1.01
(5.59, 3.57)
0.6620
1.57
(4.59, 1.46)
0.3056
Period by treatment interactiony
(95% conﬁdence interval)
P-value
1.10
(5.74, 7.93)
0.7499
* Values for model predictors are beta coefﬁcients. For treatment as a predictor,
a value of xmeans that active treatment was associated with a x lower score on the
VAS pain scale compared with control treatment. An unstructured correlation
matrix for observations within participants was used in generalized estimating
equation ﬁtting of themarginal model (1). Model 2 was conducted with exclusion of
the differential carryover effect.
y Tests whether treatment effects differed according to use in period 1 or period 2,
constituting the differential carryover effect.Prior studies have demonstrated that knee taping improves
pain30, but it is not clear that the mechanism involves a substantive
change in PF alignment. Despite numerous investigations of the
potential mechanism of the therapeutic effect of taping and bracing
in PF pain syndrome, a condition thought to result frommaltracking
of the patella, the reasons for a favorable inﬂuence of both taping
and bracing on symptoms remain unclear21e28. Some of these
studies23,24, using dynamic magnetic resonance imaging.(MRI) to
visualize PF kinematics in persons with PF pain syndrome, have
suggested that bracing may improve joint contact area and as
a consequence reduce PF joint stress. However, these studies23,24
were in younger persons with PF pain syndrome and thus they are
not immediately generalizable to persons with PF OA. Crossley
et al.45 conducted the only study evaluating effects of taping on
patella alignment in people with OA and showed that changes in
patellar alignment occurred immediately following tape applica-
tion. Whether these changes persist following prolonged use of the
tape when stretching and loosening is likely to occur is not known.
This said, the relation between PF alignment and pain has been
demonstrated in a number of studies but is not strong in any of
them18. Thus if one were able to modify PF alignment with appli-
cation of a realigning strap (such as in this study) it may have little
inﬂuence on symptoms.Fig. 4. Interaction between treatment and period effect for WOMAC Pain.
Table III
Adherence to and side effects of treatment
Adherence, mean SD hours of wear/day
from self report in diary
Active brace Control brace
Period 1 mean (SD) 4.77 (2.07) 4.32 (2.28)
n (%) <1 h 1 (3%) 3 (9%)
n (%) 1e2 h 1 (3%) 2 (6%)
n (%) 2e3 h 3 (9%) 1 (3%)
n (%) 3e4 h 6 (18%) 9 (27%)
n (%) 4e5 h 9 (27%) 7 (21%)
n (%) 5þ h 13 (39%) 11 (33%)
Period 2 mean (SD) 4.36 (1.85) 4.13 (1.99)
n (%) <1 h 1 (3%) 2 (6%)
n (%) 1e2 h 2 (6%) 2 (6%)
n (%) 2e3 h 2 (6%) 2 (6%)
n (%) 3e4 h 9 (28%) 13 (40%)
n (%) 4e5 h 10 (31%) 4 (13%)
n (%) 5þ h 8 (25%) 9 (28%)
Side effect, no. of patients
Brace slipping 2 2
Brace rubbing/irritation 3 3
Foot/ankle swelling 4 3
Increased knee pain 4 2
Other 2 2
D.J. Hunter et al. / Osteoarthritis and Cartilage 19 (2011) 792e800798It may be that the application of the realigning strap was not
successful in improving contact area and reducing joint stress. The
aperture on this brace for positioning of the patella was quite small.
As such, it is possible that the brace alonewithout the strap actually
applied compressive force to the anterior aspect of the patella,
increasing retropatellar contact force and, in so doing, mitigating
any reduction in symptoms.
It is important that we clearly state that we have demonstrated
that the application of this speciﬁc bracewas nomore effective than
the control brace in relieving symptoms for people with PF OA. This
does not reﬂect any potential beneﬁt in persons with PF pain from
other causes nor for other types of PF braces.
There are a number of limitations of this study that warrant
description. There was no control group without a brace for
comparison to the intervention because of concerns about
unblinding. Prior research has highlighted the difﬁculty of disen-
tangling the placebo effect in non-pharmacologic clinical tri-
als46e48. Consistent with this prior research, participants in our trial
demonstrated improvements in symptoms during both the control
period (brace without a realigning strap) and the active interven-
tion period (brace with the realigning strap), but wewere unable to
detect a signiﬁcant difference between the two treatment periods.
13 (16%) participants dropped out of the study potentially leading
to a loss of statistical power and introducing the potential that the
null study ﬁndings and conclusions may be due to type-2 error. We
also lacked sufﬁcient power to stratify based on severity of lateral
PF JSN at baseline to see if there was differential beneﬁt. The vari-
ability of the outcomes in this study, reﬂected in the wide conﬁ-
dence intervals for the main effect indicates some uncertainty in
the outcome. The principal ﬁnding did not detect a suggestion of
a treatment effect with the active intervention having no signiﬁcant
effect on VAS pain with only 0.7 units (0.07 cm) difference (95%
CI: 6.2, 4.8 units or 0.62 e0.48 cm). This treatment difference is
much smaller than that which is clinically relevant. According to
Angst, a clinically relevant difference in VAS pain is 1.2 cm or 12
units41,42. The attribution of symptoms to the PF or TF joint is
challenging and our classiﬁcation of those with predominant PF
involvement could lead to misclassiﬁcation. Lastly, the daily dura-
tion of treatment required to mechanically re-align the patella is
unknown, and therefore the prescribed 4 h of daily use in this study
was largely arbitrary. In the clinic, braces are often prescribed foruse only during aggravating weight bearing activity as opposed to
a set time of 4 h per day. Furthermore, we do not know if the
patient population in this study had PF malalignment.
Another possible reason for not ﬁnding an effect of bracing is
that the primary outcome measure may not have been responsive
enough to detect changes in knee pain among persons with PF OA.
Our primary outcomewas a global measure of knee pain during the
previous week. It is possible that a change in pain would have been
more evident if pain had been rated only when people were
wearing the brace, or if pain had been rated only during weight-
bearing activities when themechanical effects of the brace aremost
likely. Further some of the participants pain at the time of study
commencement (as opposed to at time of phone and visit
screening) was less than 4 on the 0e10 VAS scale potentially
mitigating detecting a treatment effect.
Given prior studies demonstrating a positive effect of taping, it
is interesting to theorize as to why braces would not work to
a similar extent. We assumed that the realigning strap would
have a similar mechanical effect to taping (the application of
a medially directed force). There are some differences in the
studies of taping to our bracing study that may lead to differences
in the effects seen during these reported trials19,20,30,45. Tape was
left on full-time for a week so it is unlikely that there is a lasting
force once the tape stretches and loosens within the ﬁrst day. In
contrast, the brace was usedw4 h per day, during which time the
applied force is likely to be nearly continuous with use. Despite
educating participants about the appropriate application of the
brace and assessing performance at each study visit, repeat
donning of the brace at home may not have been consistent. In
contrast, once the tape is applied it remains on and in that
position until removed. Our study selectively recruited persons
with PF OA whereas the prior PF taping studies in OA recruited
persons with OA in any portion of the knee joint. However this
should have led to a more favorable opportunity for our trial to
have detected an effect. Perhaps other features of the application
of tape, including the individualized application of tape by
a trained therapist and the potential to reduce fat pad impinge-
ment by taping may also be helpful.
There are also a number of important strengths of this study that
merit mentioning. All participants had meaningful symptoms at
baseline, suggesting an opportunity for detecting a real treatment
effect if there was a treatment effect to be detected. Similarly, this
study was adequately powered to detect a clinically meaningful
treatment effect on the primary outcome measure. In addition, we
speciﬁcally recruited only persons with PF OA into this study cohort
using stringent selection criteria. Other studies of patellar taping
have recruited persons with TF OA. Finally, the crossover design of
this trial facilitated both efﬁcient recruitment and strong protection
against bias due to patient-related factors.
In conclusion, this study did not demonstrate measurable clin-
ical signiﬁcance of a realigning strap on a PF brace in reducing pain
among persons with lateral PF OA. This trial represents the results
of a test of one brace in persons with lateral PF OA and does not
mitigate the potential for other PF braces to have a therapeutic
effect on this disease.
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